priors.science/reviews/systemic-lupus-erythematosus

Systemic Lupus Erythematosus

The current evidence on 28 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

28claims tracked

Weeklyre-scored against new papers

13 Established · 13 Likely · 2 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

SignalClaimStandingEvidence certaintyCorpus

StableSystemic lupus erythematosus is independently associated with a 3-to-5-fold increased risk of premature atherosclerosis and cardiovascular events beyond the contribution of traditional cardiovascular risk factors.SLE CVDEstablished92%—

StableHydroxychloroquine reduces the rate of disease flares and should be prescribed to all patients with systemic lupus erythematosus unless contraindicated.SLE HCQEstablished92%—

StableGlucocorticoid use exceeding 7.5 mg/day prednisone equivalent for sustained periods is independently associated with accelerated organ damage accrual in SLE, including cardiovascular, metabolic, and musculoskeletal damage.SLE GCEstablished90%—

StableCombination low-dose aspirin and heparin (LMWH or UFH) reduces pregnancy loss in antiphospholipid syndrome complicating SLE, compared with aspirin alone or no treatment.SLE PregEstablished89%—

StableBelimumab reduces disease activitySLE BLMEstablished88%—

StableHydroxychloroquine use is independently associated with improved long-term survival in systemic lupus erythematosus.SLE HCQEstablished88%—

StableMycophenolate mofetil achieves equivalent or superior induction remission rates compared to intravenous cyclophosphamide for proliferative lupus nephritis with a more favourable toxicity profile.SLE LNEstablished88%—

StableHydroxychloroquine continuation during pregnancy reduces SLE disease flares without harming fetal outcomes, and its use is recommended for all pregnant SLE patients.SLE PregEstablished88%—

StableVoclosporin added to mycophenolate mofetil and low-dose steroids significantly improves complete renal response rates in active proliferative or membranous lupus nephritis compared with standard of care alone.SLE VocEstablished87%—

StableAnifrolumab reduces cutaneous lupus disease activity (CLASI score) and is effective for skin-predominant SLE manifestations.SLE AniEstablished85%—

StableBelimumab improves lupus nephritis outcomesSLE BLMEstablished85%—

StableReducing hydroxychloroquine dosing to ≤5 mg/kg real body weight reduces retinal toxicity risk without significantly increasing flare rates in patients with stable low disease activity.SLE HCQEstablished85%—

StableAchieving lupus low disease activity state (LLDAS) for at least 50% of follow-up time is associated with significantly reduced damage accrual and improved quality of life compared with persistent active disease.SLE LdaEstablished85%—

StableMycophenolate mofetil is superior to azathioprine for maintenance therapy of lupus nephritis, reducing treatment failure and renal relapse.SLE LNLikely84%—

StableAnifrolumab reduces SLE disease activity across organ domains compared with placebo in patients with moderate-to-severe disease on standard background therapy, with particular efficacy for cutaneous and musculoskeletal manifestations.SLE AniLikely83%—

StableObinutuzumab added to standard therapy significantly improves complete renal response rates in active proliferative lupus nephritis compared with placebo plus standard therapy.SLE ObiLikely79%—

StableVoclosporin maintains renal remission benefit at 2 years without significant cumulative loss of eGFR compared with placebo, supporting a favourable long-term renal safety profile.SLE VocLikely78%—

StableMultitarget therapy combining mycophenolate mofetil, a calcineurin inhibitor (tacrolimus), and low-dose steroids achieves higher complete renal remission rates at 24 weeks than cyclophosphamide monotherapy for lupus nephritis induction.SLE LNLikely77%—

StableAdd-on therapy with belimumab or anifrolumab enables glucocorticoid tapering in SLE patients who would otherwise require sustained moderate doses, reducing cumulative steroid exposure.SLE GCLikely75%—

StableUpadacitinib 30 mg daily significantly improves SLE disease activity and reduces flares compared with placebo in a Phase 2 trial, establishing efficacy signal for JAK1 inhibition in SLE.SLE JAKLikely75%—

StableHydroxychloroquine use is associated with reduced risk of thrombotic events, cardiovascular events, and antiphospholipid antibody-mediated thrombosis in SLE patients.SLE CVDLikely73%—

StablePersistently elevated anti-double-stranded DNA antibodies and low complement levels identify SLE patients with higher disease activity burden and predict those most likely to benefit from escalation to biologic therapy.SLE LdaLikely73%—

StableHydroxychloroquine whole-blood concentration monitoring identifies non-adherent patients and predicts flare risk, with levels below 500 ng/mL associated with significantly higher flare rates.SLE HCQLikely72%—

StableEarly complete renal response predicts long-term outcomeSLE LNLikely71%—

StableHigh interferon gene signature score at baseline enriches for response to anifrolumab, with IFN-high patients showing consistently larger treatment benefits than IFN-low patients.SLE AniLikely70%—

StableEarly belimumab predicts better remissionSLE BLMLikely65%—

StableObinutuzumab effective after rituximab failureSLE ObiUncertain55%—

StableBaricitinib 4 mg does not achieve statistically significant SRI-4 response versus placebo in the overall SLE population across Phase 3 trials, though clinically meaningful benefits emerge in high-disease-activity subgroups.SLE JAKUncertain52%—

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely65–84%Well supported, with some gaps or indirect evidence.

Uncertain40–64%Mixed or limited evidence. Genuinely open.

Doubtful15–39%Little support; the weight of evidence leans against it.

Refuted< 15%The evidence contradicts it — confidently false as stated.

Recent signal

strengthenedNew evidence raised the certainty since the last review.

weakenedNew evidence lowered the certainty since the last review.

newA claim added to the review recently.

StableNo recent change to the standing.

Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.

Update your priors.Track this topic